Diamond Shruumz Candies Under Investigation Following Reports of Illness and Deaths
Authorities are investigating Diamond Shruumz microdosing candies as they are linked to a troubling rise in severe health issues, including two deaths. The Food and Drug Administration (FDA) has reported a significant increase in the number of illnesses associated with these candies, prompting urgent public health concerns.
As of the latest update, the FDA has confirmed that 74 individuals across 28 states have fallen ill after consuming Diamond Shruumz products. Among these cases, 62 people required medical attention, and 38 were hospitalized. The investigation is ongoing, with two deaths now being examined for potential connections to the candies.
This latest information marks an increase from the previous week, where 69 illnesses and 36 hospitalizations were reported, along with one death. The FDA’s investigation began on June 7, when only eight cases had been identified from four states. The alarming reports initiated a comprehensive inquiry involving the FDA, the Centers for Disease Control and Prevention (CDC), and local health authorities.
Concerns were first raised by the Arizona Poison and Drug Information Center, which reported instances of individuals experiencing seizures and requiring intubation after consuming the candies. Steve Dudley, the center’s director, emphasized the seriousness of the situation, stating, “There is clearly something toxic occurring with Diamond Shruumz’s products.”
In response to the escalating health crisis, Prophet Premium Blends, the parent company of Diamond Shruumz, announced a recall of all products, including various flavors of chocolate bars, gummies, and candy cones. However, despite the recall, the specific ingredient responsible for the severe reactions remains unidentified.
The candies are marketed as microdosing products, which implies they may contain psychedelic substances. Nevertheless, the company has not released a complete list of ingredients, only referring to a proprietary blend of nootropic and functional mushrooms, which may include non-hallucinogenic varieties like Lion’s Mane, Reishi, and Chaga.
Recent testing by the FDA revealed concerning findings. Samples of two Diamond Shruumz chocolate bars were found to contain 4-AcO-DMT, a synthetic psychedelic compound similar to psilocybin, the active ingredient in hallucinogenic mushrooms. This substance is classified as a Schedule I controlled substance by the Drug Enforcement Administration (DEA), indicating its potential for abuse and lack of accepted medical use.
As the investigation continues, health officials are urging consumers to avoid Diamond Shruumz products until further notice. The rising number of illnesses and hospitalizations serves as a stark reminder of the potential dangers associated with unregulated substances marketed as dietary supplements or health products.
Public health experts are closely monitoring the situation as they work to understand the implications of these findings. The FDA and CDC are collaborating with poison control centers and local health departments to ensure that the public is informed and protected from further risks.
Consumers are advised to report any adverse reactions they may experience from using these products to their healthcare providers and local health authorities. This information is crucial for tracking the scope of the issue and ensuring that appropriate measures are taken to safeguard public health.
The situation remains fluid, and health officials are committed to providing updates as new information becomes available. The investigation into Diamond Shruumz candies underscores the importance of regulatory oversight in the health and wellness industry, particularly as the popularity of microdosing and similar trends continues to grow.
